Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing [Yahoo! Finance]
Dyne Therapeutics (DYN) had its "overweight" rating reaffirmed by Morgan Stanley.
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Dyne Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]